Gritstone bio (GRTS) Awarded BARDA Contract to Conduct Comparative Phase 2b Study Evaluating Next-Generation Vaccine Candidate for COVID-19 Valued at up to $433 Million Sep 27, 2023 04:04PM
Gritstone Oncology Inc. (GRTS) Presents 6-month Neutralizing Antibody (nAb) Data Apr 17, 2023 07:02AM
Gritstone Oncology Inc. (GRTS) Presents Positive Results from Two Phase 1 CORAL Studies Oct 25, 2022 07:05AM
Gritstone Oncology Inc. (GRTS) Reports Positive Results from First Cohort of a Phase 1 Study (CORAL-BOOST) Evaluating a T Cell-Enhanced Self-Amplifying mRNA (samRNA) Vaccine Against COVID-19 Jan 4, 2022 07:00AM
Omicron COVID-19 Variant has Minimal Impact on the T Cell Epitopes Contained in Gritstone Oncology's (GRTS) Self-Amplifying mRNA COVID-19 Vaccines Nov 29, 2021 07:04AM


Nov 10, 2021 07:00AM Gritstone Oncology Inc. (GRTS) Reports Positive Non-human Preclinical Data with Second-Generation COVID-19 Vaccine Against SARS-CoV-2
May 3, 2021 08:00AM Gritstone Oncology Changes its Name to Gritstone bio to Reflect Expanded Therapeutic Focus
May 3, 2021 08:00AM Gritstone Oncology Changes its Name to Gritstone bio to Reflect Expanded Therapeutic Focus
Mar 11, 2021 09:01AM Gritstone Reports Fourth Quarter and Full Year 2020 Financial Results and Business Highlights
Mar 11, 2021 09:01AM Gritstone Reports Fourth Quarter and Full Year 2020 Financial Results and Business Highlights
Jan 19, 2021 09:27AM Pre-Open Stock Movers 01/19: (ACRS) (GEVO) (GM) Higher; (PRPH) (EDIT) (MGI) Lower (more...)
Jan 19, 2021 06:09AM Gritstone Oncology (GRTS) Reports Advancement of 2nd Generation COVID-19 Vaccine 'CORAL' Program with Support from NIAID